TopoⅡα在乳腺癌中的表达与蒽环类药物敏感性的分析

Analysis between expression of topoisomerase Ⅱα and sensitivity of epirubicin in patients with breast cancer

目的探讨乳腺癌组织中TopoⅡα的表达及其与一线应用蒽环类药物化疗疗效的关系。方法应用免疫组化法检测TopoⅡα在63例乳腺癌组织中的表达并分析其意义。结果 TopoⅡα在乳腺癌组织中的阳性表达率为73.0%。TopoⅡα的阳性表达与年龄、肿瘤大小、位置、有无腋窝淋巴结转移及ER、PR的表达无明显相关性(P>0.05),而与Her-2的表达有关(P=0.026),且呈正相关性。应用蒽环类药物化疗的患者中,TopoⅡα阳性表达者有效率是TopoⅡα阴性表达者的3.077倍(P=0.032)。TopoⅡα阳性表达组的无病进展期较TopoⅡα阴性表达组明显延长。结论 TopoⅡα的表达对乳腺癌患者化疗药物的选择及预后的判断具有重要的指导价值。

Objective To explore the expression of Topo IIa and the relationship between the expression of TopoHca and the response to anthracycline-eontaining first-line regimens in Breast carcinoma. Methods By using immunohistoehemieal method,the expression and Clinical significance were detected in 63 cases of breast carcinoma. Results In breast carcinoma tissues,the positive expression rate of TopoIIa was 73.0%.The expression of Topo II a was associated with Her-2（P=0.O26）,but the expression of Topo II a in the patients＇ age,tumor size,site,lymph node metastasis,ER and PR was not significant（P 〉 0.05）. The effective rate of Topo 11 a positive expression applying anthracene ring chemotherapy drugs was 3.077 times than Topo lIa negative expression（P=0.032）.The time to progression of the group of Topo II a positive expression was significantly longer than the group of Topo II a negative expression. Conclusion The expression of Topo lIa in Breast carcinoma contributes to the selection of drug in chemotherapy and prognosis evalation of breast cancer.